A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.

Jin-Cherng LienChi-Li ChungTur-Fu HuangTsung-Chia ChangKuan-Chung ChenGing-Yan GaoMing-Jen HsuShiu-Wen Huang

Published in: British journal of pharmacology (2019)

Jzu 17 may inhibit endothelial remodelling and suppress angiogenesis through targeting VEGF-A-VEGFR-2 signalling. These results also suggest Jzu 17 as a potential lead compound and warrant the clinical development of similar agents in the treatment of cancer and angiogenesis-related diseases.

Keyphrases

vascular endothelial growth factor
endothelial cells
papillary thyroid
wound healing
drug delivery
risk assessment
combination therapy
squamous cell
lymph node metastasis